| BCR can be considered as a candidate tumor suppressor gene localized on chromosome 22q which may be involved in meningioma pathogenesis. | None |
| The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. | leukemia, |
| Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. | leukemia, |
| Transposition of duplicated chromosomal segment involving fused BCR-ABL gene or ABL oncogene alone in chronic myelocytic leukemia and Ph chromosome-positive acute leukemia with complex karyotypes. | leukemia, |
| oncogenic transformation by BCR-ABL may increase susceptibility of leukemic progenitors to NK cell cytotoxicity by a mechanism involving overexpression of ICAM-1 | leukemia, |
| Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells. | leukemia, |
| Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia. | leukemia, |
| Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice. | leukemia, |
| Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. | leukemia, |
| The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells. | leukemia, |
| Frequency of BCR-ABL fusion oncogene in Pakistani childhood acute lymphoid leukemia (ALL) patients reflects ethnic differences in molecular genetics of ALL. Comment onComment on: Ethnic differences in the frequency of subtypes of childhood acute lymphoblastic leukemia: results of the Malaysia-Singapore Leukemia Study Group. | leukemia, |
| The incidence of BCR-ABL fusion oncogene in Pakistani patients with childhood acute lymphoid leukemia is diferent from other populations. | leukemia, |
| Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia. | leukemia, |
| Bcr-Abl oncogene is responsible for the initial phase of chronic myelogenous leukemia, which is effectively treated by the Bcr-Abl inhibitor imatinib. | leukemia, |
| Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation. | leukemia, |
| BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. | leukemia, |
| A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes. | neoplasm, |
| Bcr-Abl stability and oncogenic signaling in chronic myeloid leukemia (CML) cells are under the control of Jak2. | leukemia, |
| Bcr-Abl oncogene stimulates Jab1 expression via cooperative interaction of beta-catenin and STAT1 in chronic myeloid leukemia cells. | leukemia, |
| Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. | leukemia, |